摘要
Abstract
Objective To investigate the clinical effect of roxallistat capsuls combined with recombinant human erythropoietin(rHuEPO)injections in the treatment of uremia complicated with renal anemia patients.Methods Patients with uremia complicated with renal anemia were divided into control group and treatment group according to the cohort method.The control group was treated with rHuEPO,with 1.0 × 104-2.0 × 104 U per week,intravenously injected,used in 1-2 doses.The treatment group was treated with roxallistat on the basis of the control group.Patients weighing less than 60 kg took 100 mg each time,and patients weighing 60 kg or more took 120 mg each time,orally,three times a week.Both groups were treated continuously for 6 months.Compared of the clinical efficacy between the two groups of patients.Hemoglobin(Hb),red blood cell count(RBC),absolute neutrophil/absolute lymphocyte count(NLR),absolute platelet/absolute lymphocyte count(PLR),hematocrit(Hct),serum iron(SI),serum ferritin(SF),transferrin(TRF),hepcin(Hepc),transferrin saturation(TSAT),renal function indexes,oxidative stress indexes and inflammatory factors before and after treatment were compared between the two groups,and safety analysis was conducted.Results The total effective rate of treatment group 91.67％(44 cases/48 cases)was higher than the control group 75.00％(36 cases/48 cases),(P＜0.05).After treatment,Hb in treatment group and control group were(115.88±9.96)g·L-1 and(108.15±14.13)g·L-1,the RBC were(3.67±0.73)× 1012·L-1 and(2.75±0.54)×1012·L-1,NLR were(1.44±0.42)％and(2.05±0.51)％,PLR were(65.49±9.13)％and(89.75±10.24)％,Hct were(32.57±3.14)％and(28.06±2.99)％,SI were(9.45±1.70)and(8.11±1.63)μmmol·L-1,SF were(157.88±20.53)and(236.07±18.42)μg·L-1,TRF were(2.89±0.61)and(2.40±0.58)g·L-1,Hepc were(82.33±9.71)and(130.17±12.80)μg·L-1,TSAT were(40.36±5.16)％and(29.41±4.51)％,respectively,the differences were all statistically significant(all P＜0.05).The main adverse drug reactions in the control group were elevated blood pressure,fever and gastrointestinal reactions,while those in the treatment group were elevated blood pressure,fever,abnormal blood potassium and gastrointestinal reactions.The total incidences of adverse drug reactions in the control group and the treatment group were 12.50％and 8.33％,respectively without statistically significant difference(P＞0.05).Conclusion Roxallistat combined with rHuEPO injections can improve the anemia status of patients with uremia complicated with renal anemia,improve iron metabolism,and alleviate inflammatory responses and oxidative stress.关键词
罗沙司他/重组人促红细胞生成素/尿毒症/肾性贫血Key words
roxallistat/recombinant human erythropoietin/uremia/renal anemia分类
医药卫生
